多发性内分泌肿瘤1型6例及其家系研究

目的:分析6例多发性内分泌肿瘤1型(MEN1)患者及其家系成员的临床特点,研究MEN1基因突变特征?方法:收集患者及家系成员的临床资料,提取6例患者及其各自家系成员(共13例)外周血DNA,对MEN1基因编码区9个外显子进行PCR扩增,产物直接测序?结果:家系1中2例患者和2例家系成员MEN1基因第10外显子存在杂合突变c.1378C>T,家系2中1例患者MEN1基因第2外显子存在杂合突变c.80C>G,家系3中先证者及其母亲MEN1基因第9外显子存在杂合突变c.1225T>C,其余人员均未发现突变?其中MEN1基因突变c.80C>G和c.1225T>C为新发现的突变类型,c.1378C>T为已知突变类型?结论:MEN1基因突变分析有助于MEN 1患者早期诊断及其亲属的筛查?本研究发现2种新的MEN1突变类型能增加研究者对于MEN1遗传学特征的认识?     

多发性内分泌腺瘤病1型1例及其家系的研究

目的探讨多发性内分泌腺瘤病1型(multiple endocrine neoplasia type 1,MEN1)患者的临床特征及其家系MEN1基因突变的情况。方法回顾性分析1例MEN1患者及其7名家系成员的临床资料。抽取先证者(MEN1患者)及其大伯、父亲、大哥、妹妹、侄子、大女儿、小女儿的外周抗凝血5mL,采用标准的酚/氯仿抽提法提取人血白细胞基因组DNA,运用聚合酶链式反应(PCR)、DNA测序分析技术检测MEN1基因的9个外显子。结果先证者(MEN1患者)及其父亲、大哥均为MEN1患者,大女儿、侄子均为MEN1基因突变携带者,大伯、妹妹及小女儿MEN1基因检测均未见异常。基因序列测序结果显示,正常人的终止密码子为TGC,而MEN1患者位于第10号外显子上第1 227位的核苷酸发生了C>A的杂合突变,终止密码子TGA提前出现,menin蛋白截短,MEN1基因突变。结论 MEN1基因检测不仅对患者的诊断具有重要的意义,也为患者亲属的早期诊断和临床干预提供了可靠的依据。     

多发性内分泌腺瘤病Ⅰ型一例报告

作者报道一例多发性内分泌腺瘤病 Ⅰ型(MENⅠ型),经手术及病理证实病变除累及胰腺、甲状旁腺外,尚有甲状腺,临床较少见。对手术中发现多数性胰腺或甲状旁腺肿瘤的患者,要警惕MEN的存在,以利早期诊断及治疗。     

多发性内分泌腺瘤综合征家系MEN1基因突变及功能分析

目的对一例多发性内分泌腺瘤综合征（multiple endocrine neoplasia type1,MEN1）家系进行基因突变检测及功能分析,以探讨MEN1发病的分子机制。方法对家系两名确诊患者及其他6名成员进行相关生化检查,留取外周血液标本,提取基因组DNA,采用PCR方法扩增MEN1基因所有编码序列,包括9个外显子及外显子／内含子边界,并进行直接测序。免疫组织化学法对2名患者肿瘤组织menin蛋白进行检测。结果2名患者MEN1基因第三外显子存在插入突变C．433-434ins CTTC,可导致开放阅读框移位并提前出现终止密码子。家系其他成员未发现MEN1基因突变。患者肿瘤组织中无menin蛋白表达。结论一种新型的MEN1基因突变形式被定位,这将有利于MEN1疾病的早期分子诊断。     

多发性内分泌腺瘤病2A型二例并文献复习

目的 探讨多发性内分泌腺瘤病(MEN)2A型的临床特点及诊疗方法.方法 结合文献总结我院收治的2例MEN 2A型的诊治经验.结果 B超、CT及实验室检查发现甲状腺髓样癌及嗜铬细胞瘤,2例均诊断为MEN 2A型,予以手术切除肿瘤.结论 MEN 2A型的诊断主要依赖相应的B超、CT及实验室检查,早期诊断、早期治疗是提高疗效的关键,手术是目前主要的治疗手段.     

2型多发性内分泌肿瘤诊治（附2例）

多发性内分泌肿瘤（multiple endocrine neoplasm,MEN）是指一个患者同时有3个以上内分泌腺发生病变,临床多表现为受累的内分泌腺功能亢进.近年我科收治MEN 2a及MEN 2b型各1例,现报告如下.     

多内分泌腺瘤病研究进展

多内分泌腺瘤病1型(MEN1)发生的重要原因是MEN1基因突变,导致肿瘤细胞11号染色体不同程度的杂合缺失,menin蛋白消失,临床主要表现有甲状旁腺腺瘤、胃肠胰腺内分泌肿瘤和垂体前叶瘤.多内分泌腺瘤病2型(MEN2)主要由原癌基因RET突变所致,又分为MEN2A和MEN2B,临床表现为甲状腺髓样癌、嗜铬细胞瘤、甲状旁腺增生和黏膜神经纤维瘤.RET基因突变类型有一定的规律性,即基因型和表现型之间有非常好的相关性.本文将主要介绍MEN1和MEN2发生机制方面的最新研究进展.     

多内分泌腺瘤病研究进展

多内分泌腺瘤病1型(MEN1)发生的重要原因是MEN1基因突变,导致肿瘤细胞11号染色体不同程度的杂合缺失,menin蛋白消失,临床主要表现有甲状旁腺腺瘤、胃肠胰腺内分泌肿瘤和垂体前叶瘤。多内分泌腺瘤病2型(MEN2)主要由原癌基因RET突变所致,又分为MEN2A和MEN2B,临床表现为甲状腺髓样癌、嗜铬细胞瘤、甲状旁腺增生和黏膜神经纤维瘤。RET基因突变类型有一定的规律性,即基因型和表现型之间有非常好的相关性。本文将主要介绍MEN1和MEN2发生机制方面的最新研究进展。     

胰岛素瘤15例临床诊治分析

背景 胰岛素瘤是常见的功能性胰腺神经内分泌肿瘤,症状复杂多变,误诊率高,定位诊断及最佳治疗是胰岛素瘤诊治过程中的重大挑战。目的 总结胰岛素瘤的诊治经验。方法 回顾性分析2009—2019年于承德医学院附属医院接受外科手术治疗的15例胰岛素瘤患者的临床资料,总结其临床表现、定性诊断、定位诊断、手术方式、术后情况及随访资料。结果 15例患者中单发13例,多发2例,其中1例合并多发内分泌肿瘤1型(MEN-1)。15例患者均有Whipple三联征表现,胰岛素释放指数(IRI/G)均>0.3。15例患者均行经腹超声检查,无阳性发现;行胰腺强化CT检查,阳性14例,阴性者进一步行MRI检查发现病灶。15例患者均行手术治疗,9例行肿瘤摘除术,5例行胰体尾切除术(4例腹腔镜手术,1例开腹手术),MEN-1患者行保留幽门的胰十二指肠切除术(PPPD)+胰尾肿瘤摘除术,术后病理均为良性胰岛素瘤。术后临床相关性胰瘘(B/C级)4例,无围术期死亡患者。术后患者血糖均恢复正常且随访未见肿瘤复发及新发糖尿病患者。结论 Whipple三联征结合IRI/G是术前定性诊断的主要依据。胰腺增强CT及MRI是术前一线...     

多发胰岛细胞瘤1例

患者,女,60岁,反复晕厥3年入院.每次发作时伴头晕、黑矇、出冷汗、心慌,进食(尤其是口服糖水)后缓解.无头痛、心悸;无腹胀、腹痛.患者体重60 kg,身高145 cm.2011年3月11日入住我院内分泌内科.血糖监测空腹血糖值在1.2～2.8 mmol/L之间.血清胰岛素波动在56.9～1 562.9 pmol/L(正常值13.6 ～164.7 pmol/L),胰岛素释放指数＞0.6(正常值＜0.3).超声胃镜提示胰体及胰尾背侧低回声占位,MRI提示胰尾部异常信号灶,诊断为胰岛细胞瘤.3月21日转入胃肠腺体外科.术前行64层 CT增强扫描提示胰体及胰尾部2个结节,考虑胰岛细胞瘤可能性大(图1).于3月29日在气管插管全麻下行手术切除肿瘤.术中在胰尾部与胰体尾之间切除大小两个肿物,直径分别约为2.8 cm和1.9 cm.     

Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases

The susceptibility gene for hereditary Medullary Thyroid Carcinoma (MTC) is the RET proto-oncogene. The aim of this study was to evaluate the prevalence of common germline RET mutations in exons 10 and 11 among Iranian MTC patients. Fifty-seven non-related MTC patients were examined in this study (Females: Males =1.2:1.0, Mean age = 40.0 +/- 11.5 years) and the existence of mutations was assessed through the PCR-RFLP technique. The only Multiple Endocrine Neoplasia type 2A (MEN2A) patient displayed a C634W mutation in exon 11. Among 53 apparently sporadic MTC patients, one patient showed a C620R mutation in exon 10 and two other patients displayed C624Y mutations in exon 11 of RET proto-oncogene. Neither the only Multiple Endocrine Neoplasia type 2B (MEN2B) patient nor two Familial MTC patients was found to carry germline mutations in exons 10 and 11. This study reports, for the first time, the prevalence of common RET mutations among Iranian, apparently sporadic MTC patients, underlining the critical importance of screening for RET mutations in such patients.     

Mutation analysis in a Chinese family with multiple endocrine neoplasia type 1

Background Multiple endocrine neoplasia type 1 （MEN1） by germline mutations of the tumor suppressor gene MEN1. with MEN1. Methods A large Chinese family with MEN1 was collected MEN1 gene were amplified and sequenced. is an autosomal dominant cancer syndrome which is caused This study aimed to identify mutations in a Chinese pedigree All of the coded regions and their adjacent sequences of the Results In this family, a heterozygous cytosine insertion in exon 10 （c.1546_1547insC） inducing a frame shift mutation of MEN1 was found in the proband and the other two suffering members of his family. This mutation was linked to a novel single nucleotide polymorphism （SNP）in intron 3 （IVS3＋18C〉T）. Conclusions The mutation in exon 10 of MEN1 gene might induce development of parathyroid hyperplasia and pituitary adenoma and cosegregate with MEN1 syndrome. The significance of the new found IVS3＋18C〉T of MEN1 needs a further investigation.     

RET基因C634Y突变致多发性内分泌腺瘤病2A型一例报道并文献复习

多发性内分泌腺瘤病2A型（MEN2A）是多发性内分泌腺瘤病2型（MEN2）的一种,临床通常表现为甲状腺髓样癌（MTC）、嗜铬细胞瘤（PHEO）及甲状旁腺功能亢进。研究表明MEN2A由10号染色体RET基因突变导致。本文报道了一例由RET基因C634Y突变导致的MEN2A患者,并对其家族成员进行了基因检测,绘制系谱图。基因检测结果显示患者同胞及同胞的子女存在C634Y突变。通过本病例诊疗结合文献复习,提示临床当患者出现内分泌腺体肿瘤时,需引起警惕,应对患者其他内分泌腺体进行进一步检查,并进行RET基因检测,以防出现误诊、漏诊,实现早期治疗,提高治疗效果,改善患者预后。MEN2A患者亲属也应进行RET基因检测。     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia （MEN） is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism （PHPT）, 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918.48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple foci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia (MEN) is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918. 48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple loci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia (MEN) is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918. 48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple loci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia (MEN) is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918. 48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple loci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia (MEN) is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918. 48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple loci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.     

Diagnosis and surgical treatment of multiple endocrine neoplasia

Background Multiple endocrine neoplasia (MEN) is relatively rare. But more patients could be found by detailed examination. We discuss the diagnosis and surgical treatment of MEN. Methods The clinical data of 95 MEN cases were retrospectively analyzed. There were 30 cases of MEN1 including 19 cases from 6 families. The MEN1 gene mutation was detected in 81.48% of cases admitted after 1997. There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid. Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved. Three patients had neither clinical symptoms nor biochemical changes, and was diagnosed by MEN1 gene mutation. Six patients presented with nephrolithasis and 6 patients had impaired pancreatic endocrine function. There were 60 cases of MEN2a and 5 cases of MEN2b. 58 cases of MEN2a belongs to 19 kindreds. All MEN2a patients but one presented RET gene mutation in codon 634, and all MEN2b cases had mutation in codon 918. 48 cases of MEN2a had thyroid masses with elevated calcitonin levels. 27 patients had pheochromocytoma including 12 cases of multiple loci and 5 malignancy. 13 patients presented with hyperparathyroidism. 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid. Among them, 3 patients had bilateral pheochromocytoma. Results In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation. Insulinomas were enucleated in 4 patients. Two patients underwent thymus tumor extirpation. Total thyroidectomy with bilateral dissection of regional lymph nodes was performed in 16 patients with MEN2a and nodule enucleation was performed in 9 patients. Twenty two MEN2a patients underwent pheochromocytoma enucleation including bilateral adrenal resection in 10 cases. 5 MEN2b patients underwent total thyroidectomy with bilateral lymph node dissection. Among them, 3 cases underwent bilateral adrenal operations. Conclusions MEN varies in symptoms. Germline mutation test is helpful in establishing a diagnosis. Surgical management should be aimed at the improvement of life quality in MEN1 and prevention of the fetal tumors in MEN2.